CLEVELAND, Ohio — Case Western Reserve University has licensed technology that gauges the success of AIDS treatment to Diagnostic HYBRIDS, an Athens, Ohio, medical company.
The innovation determines the drug resistance and disease strength of the virus, according to a press release. Researchers think the approach can be used to better develop a vaccine. It was created by Eric Arts, who works in the school’s department of infectious diseases.
Diagnostic HYBRIDS is headquartered in Athens but has a research lab in Cleveland. In June, both Diagnostic HYBRIDS and Case received a $5 million grant from Ohio’s Third Frontier fund to help the groups create products to address HIV, hepatitis and influenza.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Diagnostic HYBRIDS expects to next year start offering products and services to HIV physicians, drug companies and national laboratories, according to the release.
